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The self-assembly features of a family of tetrapeptides inspired in
silk structure are presented. An exhaustive study of the influence of
the terminal alkyl chain length in this process is undertaken.
Scanning electron microscopy (SEM), wide-angle X-ray diffraction
(WAXD), FTIR spectroscopy and circular dichroism are used for
the structural analysis. These compounds, as in the natural model,
self-assemble into antiparallel β-sheet structures that further 
organize to form fibrillar aggregates.  
Furthermore, some of them are capable of forming a crowded 
network that entraps the solvent leading to physical gels with 
different microscopic morphologies. A model for the assembly 
process is proposed. 
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Introduction 
Nature’s high complexity and efficiency has always attracted 
attention of scientists, firstly to unravel its fascinating structures 
and processes and subsequently intending to imitate the beauty and 
harmony of them. For instance, mimicking the natural control of 
biomolecules conformation at the different levels of complexity 
and function has been an appealing goal. In this sense the study of 
protein structure and function has created a wide interest.[1, 2] It is 
well known that the different organization levels play an important 
role in different structural and functional proteins. For example, 
structural proteins (i.e. collagen, elastin and silks) base their 
physical properties in different aspects of their secondary structure. 
On the other hand, precisely folded switch points determine the 
active sites in catalytic proteins, enzymes.[3] Furthermore, some 
devastating diseases such as amyloidogenic pathologies are related 
to anomalous protein folding that induces precipitation of toxic 
plaques. Recently, intense research has been devoted to the 
understanding of the amyloid aggregation mechanisms as well as to 
the development of strategies to prevent this unwanted process.[4]  
In this context, the study of model systems, including peptides and 
small peptidomimetics, that self-assemble into fibrillar aggregates 
may help to determine the molecular basis for such processes.[5-8] 
In connection with these studies, the formation of self-assembled 
fibrillar networks and gels from low molecular weight molecules 
has been studied extensively in the recent past. Many efforts in this 
field are directed towards an understanding of the role that the 
different structural elements present in the gelators play in the non-
covalent association that yields the final fibrillar structures.[9-11] 
In the last years we have been involved in the study of low-
molecular weight gelators based on amino acids. These small 
peptidomimetic compounds self-assemble into sheet-like extended 
structures that form fibrous aggregates and gels in different 
solvents.[12] Recently, we have reported the design of a novel 
tetrapeptidic organogelator (4) based on a minimal sequence found 
in silks, Gly-L-Ala-Gly-L-Ala, and incorporating C12 alkyl chains 
at both ends of the tetrapeptide.[13] We studied its self-assembly in 
organic solvents and it was revealed that this sequence showed a 
high preference for the antiparallel assembly into β-sheets (see 
Scheme 1). 
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Scheme 1 
In natural silk proteins, specific amino acids induce a turn in the 
polypeptidic chain causing its preorganization for an antiparallel β-
sheet. In contrast, it is remarkable that in the reported gelator, that 
‘folding effect’ was driven only by non-covalent interactions. We 
believe that this naturally selected one-dimensional assembly motif 
has a great potential for the design of new functional fibrous 
nanomaterials. 
Here we report on the preparation and study of a library of 
compounds based on the variation of the terminal groups attached 
to the silk-mimetic tetrapeptide motif Gly-L-Ala-Gly-L-Ala 
(Scheme 2). Our aims include to clarify how the interplay of the 
non covalent interactions provided by apolar end moieties and the 
peptide core affect to the self-assembly of these molecules. The 
different nature of the intermolecular interactions provided by 
these moieties (van der Waals and solvophobic/solvophylic in one 
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case and hydrogen bonding in the other case) is expected to allow 
for a fine tuning of the aggregation behaviour with the use, for 
example, of a variety of solvents. We are interested in assessing 
how properties such size and aspect of the microscopic fibers, 
gelation of different solvents, antiparallel peptide arrangement or 
microcrystalline packing are changed through a family of 
structurally related molecules. 
Results and Discussion 
A library of molecules containing different aliphatic (C12, C6 or C3 
alkyl radicals) and aromatic (phenyl and 4-nitrophenyl) end-chains 
were prepared. Most of the synthesized compounds bear different 
end groups on the peptide termini and a few of them are 
"symmetrically" substituted, bearing analogous side chains on both 
ends of the peptide (compounds 4, 5 and 6). The synthesis of these 
molecules was carried out using conventional peptide chemistry 
methods (Scheme 2). A convergent approach was used and the 
tetrapeptide derivatives 4-18 were obtained by coupling the 
corresponding dipeptide derivatives using EDC or DCC as 
coupling reagents. The preparation of N-acylated dipeptides 3 was 
carried out by a Schotten-Baumann procedure. Compounds 2a-c 
were prepared by amide formation on the C-terminus of the Z-
protected dipeptides and subsequent removal of the protecting 
group. All these compounds were fully characterized by NMR and 
MS (see Experimental Section). 
 
Gelation studies. Firstly, the gelation capability of the compounds 
with alkyl end groups (4-13) in organic solvents was studied, and 
the results are collected in Table 1. In general, all compounds were 
poorly soluble and had to be heated at the boiling temperature of 
the solvent to obtain a clear solution. After cooling at room 
temperature many of them formed gels and some gave place to 
phase separation by formation of aggregates that could not be 
defined as proper gels but as weak gels or colloidal precipitates. In 
general, gels were obtained both in polar and apolar solvents, and 
most of them were transparent at their minimum gel concentration 
(mgc). 
It is interesting to compare the gelation properties of the 
compounds that present analogous alkyl chains on both ends of the 
peptide (compounds 4, 5 and 6 which present respectively C12, C6 
and C3 chains). It can be observed that in the more polar solvents 
the compound with C6 chains (5) is in general a better gelator than 
4 (C12 chains) which is not forming proper gels in alcohols. It could 
be argued that in compound 4 the long C12 end chains preclude gel 
formation in polar solvents. Although solvophobic interactions are 
expected to be important for aliphatic chains in polar solvents, it 
seems that the long and flexible C12 chains may not be contributing 
significantly to the 1-D aggregation motif shown in Scheme 1 
 
O N
H
H
N
OH
O
O
O
H2N
H
N
OH
O
O
RCOCl
N
H
H
N
OH
O
O
R
O
 H2, Pd/C
H2N
H
N
N
HO
O
R'
EDC or DCC
HOBt
N
H
H
N
O
O
R
O
N
H
H
N
N
HO
O
R'
4     R= -CH2-(CH2)9-CH3  R'=  -CH2-(CH2)10-CH3
5     R= -CH2-(CH2)3-CH3  R'= -CH2-(CH2)4-CH3
6     R= -CH2-CH3              R'= -CH2-CH2-CH3
7     R= -CH2-(CH2)9-CH3  R'= -CH2-(CH2)4-CH3
8     R= -CH2-(CH2)9-CH3  R'= -CH2-CH2-CH3
9     R= -CH2-(CH2)3-CH3  R'=  -CH2-(CH2)10-CH3
10   R= -CH2-(CH2)3-CH3  R'=  -CH2-CH2-CH3
11   R= -CH2-CH3              R'= -CH2-(CH2)10-CH3
12   R= -CH2-CH3              R'= -CH2-(CH2)4-CH3
13   R=   Ph-                      R'= -CH2-CH2-CH3
14   R= 4-NO2Ph-              R'= -CH2-CH2-CH3
15   R=   Ph-                      R'= -CH2-(CH2)4-CH3
16   R= 4-NO2Ph-              R'= -CH2-(CH2)4-CH3
17   R=   Ph-                      R'= -CH2-(CH2)10-CH3
18   R= 4-NO2Ph-              R'= -CH2-(CH2)10-CH3
19   R= PhCH2O -              R'= 4-NO2Ph-
3a R= -CH2-CH3
  b R= -CH2-(CH2)3-CH3
  c R= -CH2-(CH2)9-CH3
  d R= Ph-
  e R= 4-NO2Ph-
R'NH2
DCC, DME
O N
H
H
N
N
H
O
O
O
R'
1a R'= -CH2-CH2-CH3
  b R'= -CH2-(CH2)4-CH3
  c R'=  -CH2-(CH2)10-CH3
2a-c
 
Scheme 2 
On the other hand, if the gelation capability of compounds 5 (C6 
end chains) and 6 (C3 end chains) is compared it can be noticed 
that significant differences can be observed in solvents which 
present low or moderate polarity. For example in toluene 
compound 5 forms gels at a mgc value of 9 mM while compound 6 
is forming a precipitate. This behaviour is related to that observed, 
for instance, in dichloromethane where the compound 5 forms gel 
while compound 6 is insoluble. These results can be easily 
rationalized having in mind that hydrogen bonding interactions can 
be dominant in solvents of low to moderate polarity and that in 
these solvents the alkyl chains may play a role in the solubilisation 
of the molecules by favorable interactions with the solvent. In the 
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case of molecule 6, the reported behaviors could be ascribed to the 
fact that the C3 chains are too short. They would preclude the 
formation the long aggregates required for fiber formation due to 
the insoluble nature of the associated species. On the contrary, C6 
(and C12) chains would impart the required solubility, for example, 
in toluene. This line of reasoning would explain the fact that in the 
most apolar solvent, cyclohexane, gels are formed only with the 
compound with C12 chains, 4. 
Table 1. Gelation behavior of compounds 4-12 (5 mg/mL).a,b 
[a] Minimum gel concentration (mM) in parentheses. [b] G = gel, WG = 
weak gel, P = precipitate, Pc = colloidal, I = insoluble, A = aggregates. 
If the gelation capabilities of the compounds that present different 
alkyl chains on both ends are considered (compounds 6-12) it can 
be observed again than in apolar solvents the presence of short C3 
chains is not favorable for gel formation. For example, compounds 
6, 11 and 12 are no capable of gel formation in toluene. The only 
compound in the series that contains C3 end chains and forms gels 
in solvents of low polarity is 8 which presents a C12 chain that 
would compensate for the presence of the C3 chain on the other end. 
The data in Table 1 in general suggest that the compounds with 
similar alkyl chains on both ends are better gelators. For example, 
in acetone proper gels are only formed by compounds 5 (C6 chains 
on both ends) and 6 (C3 chains) and weak gels are formed by 
compound 4 (C12 chains) and 7 (C12, C6 chains). All the other 
compounds, which present dissimilar alkyl chains on both ends, do 
not form gels in acetone. These results suggest that in compounds 
with similar chain ends the interactions among the apolar moieties 
are strengthened as compared to the case of unsymmetrical 
compounds favoring the formation of gels. 
In order to asses in more detail the role played by the aliphatic end 
groups in gelation, the replacement of one of the alkyl tails by an 
aromatic fragment was studied.  In general, the substitution of alkyl 
moieties by aromatic moieties had a significant effect on the 
gelation behavior. For example, compound 5 (C6, C6) forms gels in 
toluene but replacement of one C6 moiety by a phenyl or 4-
nitrophenyl (compounds 15 and 16 respectively) gives place to 
insoluble materials in this solvent. A similar tendency can be 
observed for compound 4 (C12, C12) which is a good gelator in 
toluene but is transformed to a weak gelator in the case of 
compound 17 and to insoluble species in the case of 18. Clearly, 
these results indicate that in apolar solvents the aliphatic moieties 
play a relevant role for the formation of fibrillar structures which 
can not be paralleled with the use of aromatic moieties. Most likely 
aliphatic moieties provide to this family of molecules with more 
intense intermolecular interactions and a better packing capability 
as compared to analogous molecules with aromatic end groups. 
Indeed, compounds bearing two aromatic end-groups (i.e. 
compound 19) failed to form gels. 
It is interesting to note that in a solvent of intermediate polarity 
such as THF compound 6 (C3, C3) is not a gelator but its aromatic 
analogue with one phenyl end group (13) is capable of forming 
gels. This fact could be the result of improved solvation of phenyl 
moieties as compared to C3 units which would avoid precipitation 
of the aggregates. Finally, the more polar 4-nitrophenyl analogue 
(compound 14) does not form gels in the range of solvents studied.  
 
Spectroscopic studies. FT-IR spectroscopy is a useful technique to 
investigate the secondary structure of peptides and proteins.[14] For 
all the studied dialkyl compounds (4-12) the amide I band appeared 
at 1625 cm-1, what is typical for the strong H-bonding of β-sheet 
secondary structure. Moreover, a weak band appeared at 1695 cm-1 
indicating a high content of antiparallel β-sheet organization, in 
agreement with our previous results on compound 4 (see for 
instance Figure 1 for compound 5 and Supporting Information). It 
is noteworthy that FT-IR spectra of dried gels of compounds with 
aromatic end units such as compounds 15 and 17 showed the 
presence of a broad absorption band in the amide I region, with 
several overlapping peaks revealing not only an antiparallel β-sheet 
organization (1698 cm-1) but also other randomly organized 
assemblies (1682, 1668, 1650 cm-1 (see Supporting Information). 
This indicates that replacement of one of the alkyl units by a 
phenyl moiety generates weaker intermolecular interactions 
between aromatic and alkyl groups in the antiparallel arrangement 
as compared to those found in the compounds with two alkyl 
groups. In this way, the clear preference for the antiparallel 
arrangement found in compounds 4-12 is lost in the analogues with 
aromatic units 13-18 which would present also other aggregation 
modes including a parallel β-sheet disposition among them (see 
Figure 2). 
Circular Dichroism was also used to support the formation of β-
sheet type aggregates.[15] Solid state spectra of xerogels were 
recorded and, in all the cases, a pattern typical for this arrangement 
was observed; a negative band with a maximum at ca. 220 nm, and 
crossing zero at ca. 210 nm, and in some cases a positive lobe at 
195 nm (see for instance Figure 3 for compound 5 and Supporting 
Information). 
 
Solvent Compound 
 4 5 6 7 8 9 10 11 12 
Methanol A WG WG P G 
(10) 
G 
(9) 
WG A G 
(12)
Ethanol WG G 
(11) 
G 
(13) 
WG G 
(10) 
G 
(9) 
G 
(12) 
G 
(10)
G 
(12)
2-Propanol A G 
(7) 
WG G(9) G 
(3) 
G 
(7) 
G 
(5) 
A G 
(12)
Cyclohexanol S G 
(11) 
G 
(13) 
A/P G 
(10) 
G 
(9) 
G 
(12) 
G 
(10)
G 
(12)
Acetone WG G 
(11) 
G 
(13) 
WG I/A A I A P 
THF G 
(8) 
G 
(11) 
A G 
(9) 
I/A G 
(9) 
I Pc Pc 
DME A G 
(7) 
I WG WG A P A Pc 
CH3CN G 
(8) 
G 
(4) 
WG WG G 
(6) 
G 
(7) 
G 
(7) 
A G 
(12)
CH2Cl2 G 
(8) 
G 
(11) 
I G 
(9) 
WG G 
(9) 
G 
(12) 
Pc Pc 
CHCl3 G 
(8) 
G 
(11) 
I G 
(9) 
WG G 
(9) 
G 
(12) 
WG Pc 
Dioxane WG G 
(11) 
A G 
(9) 
WG WG G 
(12) 
Pc Pc 
Cyclohexane WG A/Pc A A/P A G 
(9) 
P Pc Pc 
Toluene G 
(8) 
G 
(9) 
Pc WG G 
(8) 
G 
(6) 
G 
(10) 
WG Pc 
 4
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1746.75 1483.9316001700
Abs
Wavenumber [cm-1]
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Figure 1. FT-IR of the amide C=O region of xerogel of compound 5 
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Figure 2. Proposed antiparallel and parallel arrangements for compound 15. 
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Figure 3. CD spectrum of a xerogel of compound 5 (from a toluene gel). 
X-Ray powder diffraction. Wide-angle X-ray diffraction 
(WAXD) spectra of the xerogels were in good agreement with the 
proposed β-sheet arrangement. In all the cases, a low angle sharp 
peak corresponding approximately to a calculated distance for a 
fully extended molecule was obtained. For example, for compound 
5, the WAXD data of xerogels obtained from different solvents 
provided in all the cases peaks corresponding to a periodicity of 30 
Å which fits nicely with the calculated distance for an extended 
molecule. Additionally, in all the cases, peaks assigned to a 
periodic distance of 4.4 Å were found that can be ascribed to 
extended two-dimensional layers of β-sheets that stack parallel on 
top of each other (see Figure 4 and Supporting Information for 
other compounds). 
For a given compound, there were not important differences in the 
position of the diffraction peaks between different solvents. This 
fact reveals that although macroscopic properties such as solubility 
or gelation efficiency are strongly solvent dependent, the solvent 
has a limited effect in the organization at the molecular level. Only 
some subtle differences were observed for the low-angle peaks 
related, probably, with a different degree of mobility of the tails. 
Higher angle peaks, corresponding to shorter distances in the 
microcrystalline structure, were sometimes absent, especially in 
xerogels from apolar solvents, which also showed broader bands 
than in polar ones. This is probably due to a higher extent of tail 
mobility that could provoke the presence of some folded segments 
within the chain. 
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Figure 4. Proposed packing model (top) and WAXD pattern (bottom) for 
xerogels of compound 5. 
In natural silk fibers, the antiparallel organization is achieved 
through an intramolecular turn of the polypeptidic chain being the 
repeating distance corresponding to the H-bonding direction of ca. 
9.4 Å.[16] In our case, where this turn is not present, we found two 
different situations: i) compounds bearing C12 tails, which showed 
a spacing of ca. 11 Å, and ii) compounds with shorter length tails, 
that presented shorter spacing (8.5 Å). In the first case, the greater 
chain mobility of the longest tails could explain the observed larger 
spacing, while in the second shorter tails resulted in a more 
compact packing. 
At a higher level of organization, two different packing models 
may be proposed for the arrangement of the antiparallel β-sheets, 
namely, head-to-head or head-to-tail (see Scheme 3). For 
symmetrically substituted compounds, only the head-to-tail 
packing fits with the observed low angle diffraction peaks, 
coincident with the fully extended molecular dimension. A head-
to-head packing would produce larger repeating distances than 
those obtained experimentally. Similarly, in the case of, 
unsymmetrically substituted compounds, head-to-tail packing also 
fits with the experimental data and a head-to-head packing seems 
less likely because it would cause kinks and folds in the chains 
with the result of a loss of packing efficiency. 
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Scheme 3 
Electron microscopy studies. The microscopic aspect of the gels 
and fibrillar aggregates obtained was studied by scanning electron 
microscopy. For this purpose aggregates were dried and the 
xerogels were investigated. These compounds presented a high 
tendency to form fibrillar architectures. Fibers and fibrils were 
observed in most of the cases with differences in length, stiffness 
and branching degree, revealing that these compounds have a great 
tendency to form elongated objects (Figures 5, 6 and 7). Some of 
them further entangled to form networks whereas others merged 
into rigid and long ribbons, or even fused into globular objects with 
membrane-like aspect. 
 
 
Figure 5. SEM images of xerogels from compounds 5 (A,B), 6 (C), 8 (D), 
10 (E) and 12 (F) gels in toluene. 
Although WAXD studies have revealed that all the studied 
molecules present, basically, the same organization at the 
molecular level, the gel network showed a diversity of 
morphologies depending mainly on the solvent. For instance, the 
network of xerogels obtained from toluene is formed by tiny fibrils 
of less than 100 nm width, that are fused forming bags of 
micrometer size that were probably filled by solvent in the original 
gels (Figure 5).[13] Even for compounds 6 and 12, that did not form 
strong gels, a similar morphology was observed with only subtle 
differences at the microscopic level. In difference, xerogels from 
acetonitrile (Figure 6) revealed a network made by very long and 
thin fibers, with several hundreds of nanometers in width and tens 
of micrometers in length, that in some cases appeared highly 
aligned (5 and 10) whereas in other cases showed a higher 
tendency for coiling and cross-linking (7, 8, 9 and 12). For 
xerogels prepared from alcohols (Figure 7) very long and thin 
fibers were also observed in general. However in the case of 
compound 11 a different aspect was observed in methanol. In this 
case fibers were significantly shorter and, in consequence, the 
formation of a network was not complete and isolated aggregates 
were formed instead of a strong gel. The xerogel from compound 8 
was also different but, in this case, a higher degree of cross-linking 
could be observed in agreement with the formation of a strong gel 
in that solvent. 
From this behavior, it may be concluded that, for those compounds 
that formed gels, the nature of the side chains does not seem to 
affect significantly to the microscopic aspect of the xerogel for a 
given solvent being the formation of fibrillar networks a general 
trend. Only in the cases where a strong gel was not formed, namely 
aggregates or precipitates being formed instead, different 
morphologies were observed. 
 
 
Figure 6. SEM images of xerogels from compounds 5 (A), 7 (B), 8 (C), 9 
(D), 10 (E) and 12 (F) gels in acetonitrile. 
Taking into account all the structural information discussed above 
and the fact that all these compounds, despite of showing different 
specific morphologies, assemble into fibrillar aggregates, we may 
propose a model for their hierarchical organization into 
microscopic size fibers. In a first level of organization, molecular 
entities assemble to form an antiparallel β-sheet secondary 
structure, with a vague influence of the length of the alkyl chains. 
This extended sheets stack into parallel layers separated by 4.4 Å 
in all the cases. These layers have a preferential one-dimensional 
growth that produces fibers directed by the formation of H-bonds 
parallel to their axe. This arrangement is known as the cross-β 
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structure and is typical for amyloid-like fibrils and some silk 
fibroins (Figure 8).[8, 18] 
 
 
Figure 7. SEM images of xerogels from compounds 8 (A), 10 (B), 11 (C) 
and 12 (D) gels in methanol and 5 (E) and 8 (F) in 2-propanol . 
The potential influence of side groups in the self-assembly of 
oligopeptides and its effect on the fiber packing has been 
reported.[19] In our case, as in other reported, it seems reasonable 
that the strongest interaction, H-bonding, runs parallel to the fiber 
axe, and that interactions between tails have a smaller contribution 
to the resulting elongated objects.[20] This model would explain 
why fibrillar aggregates are always found for those compounds that 
formed gels, independently of the chain length. Thus, the 
effectiveness of the interaction between tails would affect on the 
thickness of the fibers, and in some extend on the fiber length. For 
instance, packing of symmetrical tails would lead to a more stable 
situation than for unsymmetrical ones, where intercalation or 
folding may produce packing mistakes and kinks. 
 
cross β structure
Fiber axe
 
Figure 8. Propossed cross β packing. 
Conclusion 
We have studied in detail the aggregation behavior of a series of 
silk-inspired low molecular weight compounds containing a β-
sheet-like H-bonding core and apolar end groups. It has been 
shown that these molecules present a high tendency to form 
fibrillar networks that in many cases produced gels. The results 
have provided useful information on the role played by the apolar 
alkyl chains in the self-assembly. It has been noticed than the 
length of the apolar moiety can affect directly to the gelation 
capabilities of these molecules and this behavior can be associated 
to factors such as solubility and intermolecular interactions. The 
presence of similar alkyl chains on both ends of the molecule has 
been shown to improve the gelation properties, most likely due to a 
favorable packing of the β-sheet like stacks. Structural studies of 
the aggregation at the molecular level with FT-IR, circular 
dichroism and WAXD revealed that all the alkyl terminated 
gelators present an antiparallel β-sheet type arrangement. However, 
replacement of alkyl by aromatic end groups results in the 
formation of materials where different structural motifs coexist 
(antiparallel and parallel β-sheet for example). Having in mind that 
strong H-bonding interactions are possible both in the parallel and 
antiparallel arrangements, these results indicate that alkyl groups 
play a key role in the observed antiparallel structures. This fact can 
be ascribed to factors such as packing efficiency, solvophobic 
effects and favorable van der Waals interactions. Finally, a variety 
of microscopic morphologies associated with really small changes 
in molecular structure and solvent have been observed in the SEM 
study of the xerogels.  
Overall the results reveal that this is a family of versatile gelators 
because the fine tuning of their structure permits the formation of 
gels is a broad range of solvents of different polarity. Identically, 
the microscopic aspect of the material can also be regulated by 
simple structural changes and this property is interesting in fields 
associated to nanofabrication. Most interestingly, the fidelity found 
for the antiparallel β-sheet motif opens the door for the use of this 
tetrapeptidic structure as scaffold for the construction of highly 
ordered functional materials with application, for example, in 
materials science and catalysis. 
Experimental Section 
Synthesis. General procedure for compounds 1a-c: Benzyloxycarbonyl-Glycyl-L-
Alanine (3.57 mmol) dissolved in 80 mL of freshly dry DME was placed in a round-
bottomed flask with a stirrer, and immersed in an ice bath. Dicyclohexylcarbodiimide 
(DCC) (4.6 mmole) dissolved in 100mL of DME was added dropwise to the solution 
during a period of 1 h, and the mixture was kept at stirring for 2 h. Then, amine (3.5 
mmole) dissolved in dry DME was added slowly, and the mixture was shifted to room 
temperature by over night stirring. Afterward, the white suspension was filtered and 
solvent was evaporated under vacuum. The product was purified by column 
chromatogarphy on silica gel using (CH2Cl2:MeOH) as eluent. 
N-propyl-(N’-benzyloxycarbonyl-glycyl)-L-alanine amide (1a). White solid (62% 
yield). mp: 117-120 ˚C. Rf  = 0.59 (CH2Cl2:MeOH, 96:4). 1H NMR (300 MHz, 30 ºC, 
DMSO- d6) δ  0.78 (t, J = 7.2 Hz, 3H), 1.16 (d, J = 6.9 Hz, 3H), 1.30 (m, 2H), 2.93 (q, 
J = 6.6 Hz, 2H), 3.61 (d, J = 5.7 Hz, 2H), 4.19 (m, 1H), 5.01 (s, 2H), 7.35 (s, 5H), 7.41 
(t, J = 5.4 Hz, 1H), 7.80 (s, 1H), 7.94 (d, J = 7.2 Hz, 1H). 13C NMR (75 MHz, 30 ºC, 
DMSO- d6) δ  11.97, 19.23, 22.92, 44.21, 48.85, 66.14, 128.32, 128.46, 129.03, 
137.73, 157.21, 169.30, 172.55. IR cm-1; 3307, 3268, 2961, 2850, 1723, 1691, 1646, 
1542, 1267. HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd. for 
C16H23N3O4Na+, 344.1581 found, 344.1587 [M + Na]+, 665.21 [2M + Na]+, (Δ = 1.7 
ppm). 
N-hexyl-(N’-benzyloxycarbonyl-glycyl)-L-alanine amide (1b). White solid (78% 
yield). mp: 115-117 ˚C. Rf  = 0.63 (CH2Cl2:MeOH, 96:4). 1H NMR (300 MHz, 30 ºC, 
DMSO- d6) δ  0.81 (t, J = 6.3 Hz, 3H), 1.16 (m, 9H), 1.34 (t, J = 6.3 Hz, 2H), 2.97 (q, J 
= 6.3 Hz, 2H), 3.61 (d, J = 5.7 Hz, 2H), 4.21 (m, 1H), 5.01 (s, 2H), 7.35 (s, 5H), 7.43 
(t, J = 5.7 Hz, 1H), 7.77 (s, 1H), 7.93 (d, J = 7.5 Hz, 1H). 13C NMR (75 MHz, 30 ºC, 
DMSO- d6) δ  14.55, 19.20, 22.68, 26.61, 29.60, 31.60, 39.18, 44.21, 48.83, 66.13, 
128.31, 128.46, 129.02, 137.72, 157.21, 169.29, 172.47. IR cm-1; 3314, 3079, 2930, 
2857, 1736, 1674, 1653, 1536, 1256. HRMS (ESI-TOF, positive mode) m/z exp [M + 
Na]+ calcd for C19H29N3O4Na+, 386.2056; found, 386.2049 [M + Na]+, 749.32 [2M + 
Na]+, 364.22[M + H]+, (Δ = 1.8 ppm). 
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N-docecyl-(N’-benzyloxycarbonyl-glycyl)-L-alanine amide (1c). White solid (92% 
yield). mp: 121-124 ˚C. Rf  = 0.68 (CH2Cl2:MeOH, 90:10). 1H NMR (300 MHz, 30 ºC, 
DMSO- d6) δ  0.81 (t, J = 6.3 Hz, 3H), 1.15-1.25 (m, 21H), 1.34 (t, J = 5.7 Hz, 2H), 
2.97 (q, J = 6.3 Hz, 2H), 3.60 (d, J = 6 Hz, 2H), 4.19 (m, 1H), 5.01 (s, 2H), 7.33 (s , 
5H), 7.44 (t, J = 6.0 Hz, 1H), 7.76 (s,1H), 7.77 (d, J = 7.5 Hz, 1H).  13C NMR (75 
MHz, 30 ºC, DMSO- d6) δ  14.62, 19.27, 22.76, 26.97, 2C (29.37), 5C (29.66), 31.96, 
39.18, 44.23, 48.81, 66.13, 128.31, 128.44, 129.01, 137.72, 157.19, 169.25, 172.42.  
IR cm-1; 3321, 3070, 2921, 2850, 1726, 1687, 1653, 1546, 1272.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C25H41N3O4Na+, 470.2995; found, 
470.3002 [M + Na]+ 917.4327 [2M + Na]+ , 448.3202 [M + Na]+, (Δ = 1.4 ppm). 
General Procedure for compounds 2a-c: Compound 1 (1.43 mmoles) was dissolved 
in 30 mL of methanol containing 50 mg of palladium 5 wt% on activated carbon in a 
two necked-round bottom flask. Then a balloon filled with hydrogen gas was 
connected to one neck of the flask and the system was saturated with hydrogen by 
slightly opening and closing of second neck to remove air. After complete 
deprotection, the solution was filtered through celite and the filtrate was evaporated 
under vacuum. The product was purified through silica column using mixtures of 
CH2Cl2:MeOH as eluent. 
N-propyl-(N’-Glycyl)-L-alanine amide (2a). White solid (Yield: 98%). mp: 290 ˚C 
dec. Rf  = 0.37 (MeOH: CH2Cl2, 25:75). 1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.83 (t, J = 7.2 Hz, 3H), 1.17 (d, J = 7.5 Hz, 3H), 1.35-1.41 (m, 2H), 2.99 (m, 2H), 
3.10 (s, 2H) 4.55 (m, 1H), 7.90 (s, 1H), 8.02 (d, 1H).  13C NMR (75 MHz, 30 ºC, 
DMSO- d6) δ  11.96, 19.70, 22.93, 39.36, 44.93, 48.46, 172.46, 172.63.  IR cm-1; 3292, 
2967, 2850, 1646, 1545, 1458, 1254.  HRMS (ESI-TOF, positive mode) m/z exp [M + 
Na]+ calcd for C8H17N3O2Na+, 210.1213; found, 210.1176 [M + Na]+, 397.2142 [2M + 
Na]+, (Δ = 19.0 ppm). 
N-hexyl-(N’-Glycyl)-L-alanine amide (2b). White solid (Yield: 97%). mp: 82-84 ˚C. 
Rf  = 0.42 (MeOH: CH2Cl2, 25:75).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  0.82 (t, 
J = 6.6 Hz, 3H), 1.16 (m, 11H), 1.34 (t, J = 6.6 Hz, 2H), 3.00 (m, 2H), 3.03 (m, 2H), 
4.24 (m, 1H), 7.88 (t, J = 5.1 Hz, 1H), 8.02 (s, 1H).  13C NMR (75 MHz, 30 ºC, 
DMSO-d6) δ  14.77, 19.95, 22.92, 26.84, 29.85, 31.82, 39.35, 45.29, 48.62, 172.75, 
172.83.  IR cm-1; 3283, 2930, 2853, 1647, 1511, 1458, 1251.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C11H23N3O2Na+, 252.1682; found, 
252.1639 [M + Na]+, 481.2881  [2M + Na]+, (Δ = 17.0 ppm). 
N-dodecyl-(N’-Glycyl)-L-alanine amide (2c). White solid (Yield: 98%). mp: 88-89 
˚C. Rf  = 0.51 (MeOH: CH2Cl2, 25:75).  1H NMR (300 MHz, 30 ºC, DMSO-d6) δ  
0.81 (t, J = 6.3 Hz, 3H), 1.17-1.23 (m, 23H), 1.34 (t, J = 6.6 Hz, 2H), 2.97 (m, 2H), 
3.11 (s, 2H), 4.26 (m, 1H), 7.91 (t, J = 5.7 Hz, 1H), 8.28 (d, J = 6.9 Hz, 1H).  13C 
NMR (75 MHz, 30 ºC, DMSO- d6) δ  14.62, 19.48, 22.75, 26.96, 2C (29.37), 5C 
(29.65), 31.95, 39.15, 42.62, 48.81, 168.88, 172.28. IR cm-1; 3298, 2930, 2849, 1647, 
1561, 1459, 1248.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for 
C17H35N3O2Na+, 336.2621; found, 336.2663 [M + Na]+, (Δ = 10.0 ppm). 
General Procedure for compounds 3a-c: Glycyl-L-Alanine (6.8 mmole) dissolved in 
50 mL of 1 M NaOH was placed in a round-bottomed flask with an efficient magnetic 
stirrer. The flask was completely immersed in an ice bath and during reaction; stirrer 
was set in very rapid motion. To the solution, 13.6 mmol of pure acyl chloride and 10 
mL of 1 M NaOH were added dropwise at the same rate in such a way that pH of 
reaction mixture should not decrease below 10. When the reaction was complete, the 
suspension was acidified carefully with 2 M HCl. The residue obtained after filtration 
was extracted with petroleum ether to remove the fatty acid. The final dipeptide 
derivative was chromatographed on a silica gel column with MeOH: CH2Cl2mixtures 
as eluent. 
Propanoyl-glycyl-L-alanine (3a). White solid (Yield: 82%). mp:  104-107˚C. Rf  = 
0.25 (MeOH: CH2Cl2, 10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  0.94 (t, J = 
7.5 Hz, 3H), 1.22-1.25 (m, 3H), 2.07 (q, J = 7.8 Hz, 2H), 3.66 (m, 2H), 4.22 (m, 1H), 
7.96 (d, J = 5.4 Hz, 1H), 8.07 (d, J = 7.2 Hz, 1H), 12.55 (s broad, 1H).  13C NMR (75 
MHz, 30 ºC, DMSO-d6) δ  10.29, 17.80, 17.83, 28.80, 42.15, 47.93, 47.99, 169.30, 
173.72, 174.49.  IR cm-1; 3386, 3273, 3098, 2984, 2531, 1743, 1633, 1577, 1210.  
HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for C8H14N2O4Na+, 
225.0846; found, 225.0861 [M + Na]+, (Δ = 6.6 ppm). 
Hexanoyl-glycyl-L-alanine (3b). White solid (Yield: 89%). mp:  125-127 ºC.  1H 
NMR (300 MHz, 30 ºC, DMSO-d6) δ  0.81 (t, J = 6.6 Hz, 3H), 1.21-1.25 (m, 7H), 1.45 
(q, J = 7.2 Hz, 2H), 2.07 (t, J = 7.5 Hz, 2H), 3.66 (m, 2H), 4.16 (m, 1H), 7.95 (t, J = 
5.4 Hz, 1H), 8.05 (d, J = 7.5 Hz, 1H), 12.54 (s, br, 1H).  13C NMR (75 MHz, 30 ºC, 
DMSO-d6) δ  14.52, 18.00, 22.55, 25.52, 31.55, 35.82, 42.32, 48.12, 169.44, 173.20, 
174.63.  IR cm-1; 3292, 3102, 2859, 2570, 1734, 1641, 1570, 1209.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C11H20N2O4Na+, 267.1315; found, 
267.1324 [M + Na]+, 511.2747 [2M + Na]+, (Δ = 3.3 ppm). 
Dodecanoyl-glycyl-L-alanine (3c). White solid (Yield: 94%). mp: 133-135 ˚C.  1H 
NMR (300 MHz, 30 ºC, DMSO- d6) δ  0.81 (t, J = 6.0 Hz, 3H), 1.20-1.25 (m, 19H), 
1.46 (s, 2H), 2.06 (t, J = 7.2 Hz, 2H), 3.62 (m, 2H), 4.19 (m, 1H), 7.91 (t, J = 5.4 Hz, 
1H), 8.03 (d, J = 7.5 Hz, 1H), 12.45 (s, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  
14.62, 18.00, 22.77, 25.86, 29.35, 29.38, 29.50, 29.61, 29.68, 29.71, 31.98, 35.86, 
42.30, 48.08, 169.41, 172.15, 174.64.  IR cm-1; 3289, 3102, 2850, 2570, 1726, 1641, 
1570, 1208.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for 
C17H32N2O4Na+; 351.2254; found, 351.2254 [M + Na]+, 679.4482 [2M + Na]+, (Δ = 
0.0 ppm). 
Benzoyl-glycyl-L-alanine (3d). White solid (Yield: 91%). mp: 187-189 ˚C. Rf = 0.51 
(MeOH: CH2Cl2,10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  1.26 (d, J = 7.2 Hz, 
3H), 3.87 (m, 2H), 4.20 (m, 1H), 7.43-7.53 (m, 3H), 7.85 (dd, J = 6.6, J’ = 1.8 Hz, 2H), 
8.19 (d, J = 5.1 Hz, 1H), 8.65 (t, J = 7.5 Hz, 1H), 12.14 (s, broad, 1H).  13C NMR (75 
MHz, 30 ºC, DMSO- d6) δ  18.02, 42.94, 48.20, 128.00, 128.96, 132.00, 134.74, 
167.13, 169.38, 174.68.  IR cm-1; 3518, 3382, 3075,2929, 1715, 1626, 1492, 1293.  
HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for C12H14N2O4Na+; 
273.0846; found, 273.08567 [M + Na]+, 523.1891 [2M + Na]+, (Δ = 3.9 ppm). 
(4-nitro-benzoyl)-glycyl-L-alanine (3e). White solid (Yield: 89%). mp: 194-198 ˚C. 
Rf = 0.54 (MeOH: CH2Cl2, 10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  1.25 (d, 
J = 8.7 Hz, 3H), 3.92 (m, J = 6 Hz, 2H), 4.20 (m, 1H), 8.07 (d, J = 8.7 Hz, 2H), 8.25 
(m, 3H), 9.03 (t, J = 6 Hz, 1H), 12.47 (s br., 1H).  13C NMR (75 MHz, 30 ºC, DMSO- 
d6) δ  22.73, 47.75, 52.95, 128.94, 134.28, 145.16, 154.53, 170.27, 173.68, 179.38.  IR 
cm-1; 3518, 3290, 3075, 2929, 1724, 1687, 1656, 1531, 1348.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C12H13N3O6Na+, 318,0697; found, 
318.0710 [M + Na]+, (Δ = 4.0 ppm). 
General Procedure for compounds 4-12. Method 1: Compound 3 (0.567 mmoles) 
and HOBT (0.684 mmols) were placed in a round bottom flask with a stirrer and were 
dissolved in 10 mL of freshly dried DMF. The flask was immersed in an ice bath. To 
the mixture, DCC (0.73 mmole) dissolved in 5 mL was added dropwise. The mixture 
was stirred for 2 h and then, amine 2 (0.567 mmole) dissolved in dry DME was added 
dropwise. The mixture was further stirred over night at room temperature. Afterwards, 
reaction was quenched by adding excess of diethyl ether and then washed with water. 
The white product was purified through 4-5 cm packed column with silica by 
(CH2Cl2:MeOH, 90:10) firstly and then with pure methanol or ethanol. Method 2: 
Compound 3 (0.567 mmoles), HOBT (0.684 mmoles), EDC (0.627 mmoles) and 
amine 2 (0.567 mmoles) were stirred over night in 10 mL of freshly dried DMF. Then, 
DMF is evaporated under vaccum and solid material was grind, washed in excess of 
water and dried under high vacuum. 
N-dodecyl-[N’-dodecanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (4). Described 
previously.[9] 
N-hexyl-[N’-hexanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (5). Method 1. 
White solid (Yield: 89%). mp: 244-248 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO-[ d6]) 
δ  0.81 (t, J = 6.0 Hz, 3H), 1.15-1.36 (m, 21H), 1.46 (m, 2H), 2.06 (t, J = 7.2 Hz, 2H), 
2.99 (m, 2H), 3.64 (m, 4H), 4.17 (m, 2H), 7.73 (m, 1H), 7.79 (m, 1H), 8.00 (m, 1H), 
8.09 (m, 1H), 8.19 (m, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  14.42, 14.48, 
14.53, 18.37, 18.88, 22.51, 22.22, 25.48, 26.56, 29.54, 31.51, 31.57, 35.78, 42.65, 
42.84, 48.94, 49.31, 169.03, 169.94, 172.55, 173.49, 173.64.  IR cm-1; 3292, 2929, 
2859, 1696, 1626, 1545, 1448, 1233.  HRMS (ESI-TOF, positive mode) m/z exp [M + 
Na]+ calcd for  C22H41N5NaO5+  478.30 ; found, 478.2986 [M + Na]+, (Δ = 2.9 ppm). 
N-propyl-[N’-propanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide  (6). Method 2. 
White solid (Yield: 72%). mp: 274-275 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.79 (t, J = 4.5 Hz, 3H), 0.95 (t, J = 4.5 Hz, 3H), 1.15-1.21 (m, 6H), 1.34-1.42 (m, 2H), 
2.09 (q, J = 4.5 Hz, 2H), 2.96-3.02 (m, 2H), 3.62 (m, 4H), 4.22 (m, 2H), 7.71 (t, J = 
3.3 Hz, 1H), 7.79 (d, J = 4.5 Hz, 1H), 7.94 (t, J = 3.3 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 
8.15 (t, J = 3.3 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  10.64, 12.18, 18.77, 
19.21, 23.15, 29.16, 39.61, 42.87, 43.07, 49.13, 49.43, 169.17, 170.06, 172.72, 173.61, 
174.29.  IR cm-1; 3291, 3088, 2970,2876, 1694, 1626, 1543, 1444, 1235.  HRMS (ESI-
TOF, positive mode) m/z exp [M + Na]+ calcd for C16H29N5NaO5+  394.2061; found,   
394.2068 [M + Na]+, (Δ = 1.7 ppm). 
N-hexyl-[N’-dodecanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (7). Method 1. 
White solid (Yield: 89%). mp: 258-263 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.81 (t, J = 6.9 Hz, 3H), 1.19 (s, 31H), 1.33 (t, J = 6.6 Hz, 2H), 1.43 (t, J = 6.6 Hz, 2H), 
2.06 (t, J = 6.9 Hz, 2H), 3.00(s, 2H), 3.64 (m, 4H), 4.15 (m, 2H), 7.70 (m, 2H), 7.95 (s, 
1H), 8.06 (m, 2H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  14.54, 14.60, 18.36, 
18.39, 18.47, 18.97, 22.68, 22.74, 25.81, 26.60, 29.35, 29.47, 29.58, 29.65, 29.68, 
31.60, 31.94, 35.82, 39.19, 42.65, 42.85, 48.90, 49.23, 168.90, 169.84, 172.42, 173.35, 
173.40.  IR cm-1; 3296, 2925, 2854, 1696, 1627, 1560, 1449, 1238.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for  C28H53N5NaO5+ 562.3939 ; found, 
562.3918 [M + Na]+, (Δ = 3.7 ppm). 
N-propyl-[N’-docecanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (8). Method 1. 
White solid (Yield: 92%). mp: 259-262 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.80 (m, 6H), 1.191-1.24 (m, 20H), 1.37-1.49 (m, 6H), 2.09 (t, J = 7.5 Hz, 2H), 2.97 (s, 
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2H) 3.68 (m, J = 4.5 Hz, 4H), 4.20 (m, 2H), 7.50 (s, 1H), 7.58 (s, 1H), 7.73 (s, 1H), 
7.83 (s, 1H), 7.95 (s, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  11.97, 14.63, 
18.56, 19.01, 22.77, 22.92, 25.84, 29.36, 29.38, 29.49, 29.60, 29.68, 29.70, 31.97, 
35.82, 39.38, 42.62, 42.83, 48.90, 49.19, 168.93, 169.81, 172.50, 173.32, 173.34.  
HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for C25H47N5NaO5+ 
520.3469 ; found, 520.3478 [M + Na]+, (Δ = 1.7 ppm). 
N-dodecyl-[N’-hexanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (9). Method 1. 
White solid (Yield: 86%). mp: 264-267 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.82 (t, J = 6.3 Hz, 3H), 1.15-1.21 (m, 33H), 1.45 (m, 2H), 2.09 (t, J = 7.2 Hz, 2H), 
3.01 (m, 2H), 3.66 (m, 4H), 4.17 (m, 2H), 7.60 (s, 1H), 7.69 (d, J = 6.6 Hz, 1H), 7.88 
(s, 1H), 8.01 (s, 1H), 8.14 (s, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ 14.39, 
14.49, 18.46, 18.94, 22.47, 22.67, 25.11, 25.45, 26.97, 29.29, 29.36, 3C (29.61), 31.57, 
31.91, 35.88, 39.21, 39.63, 42.92, 43.08, 49.03, 49.36, 168.95, 169.88, 172.47, 173.35, 
173.38.  IR cm-1; 3293, 2925, 2854, 1696, 1622, 1560, 1448, 1235.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C28H53N5NaO5+ 562.3939; found, 
562.3923 [M + Na]+, (Δ = 2.8 ppm). 
N-propyl-[N’-hexanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (10). Method 1. 
White solid (Yield: 87%). mp: 244-245 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.78 (m, 6H), 1.16-1.23 (m, 10H), 1.34-1.51 (m, 4H), 2.06 (t, J = 7.5 Hz, 2H), 2.94 (q, 
J = 6.9 Hz, 2H), 3.64 (m, 4H), 4.16 (m, 2H), 7.72 (t, J = 5.4 Hz, 1H), 7.81 (d, J = 7.5 
Hz, 1H), 7.97 (t, J = 5.4 Hz, 1H), 8.09 (d, J = 6.6 Hz, 1H), 8.18 (t, J = 5.4 Hz, 1H).  
13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  11.96, 14.25, 18.58, 19.01, 22.56, 22.92, 
25.52, 31.55, 35.78, 42.63, 42.83, 48.90, 49.18, 49.27, 168.94, 169.81, 172.50, 173.34, 
173.37.  IR cm-1; 3293, 2961, 2854, 1696, 1622, 1542, 1444, 1248.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C19H35N5NaO5+ 436.253 ; found, 
436.2520 [M + Na]+, 413.2654 [M + H]+, (Δ = 2.2 ppm). 
N-dodecyl-[N’-propanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (11). Method 2. 
White solid (Yield: 98%). mp: 234-238 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.81 (t, J = 6.9 Hz, 3H), 0.85 (t, J = 7.5 Hz, 3H), 1.15-1.22 (m, 11H), 1.35 (s, 2H), 
2.07 (q, J = 7.5 Hz, 2H), 2.99 (s, 2H), 3.68 (m, 4H), 4.17 (m, 2H), 7.74 (s, 1H), 7.82 (d, 
J = 6 Hz, 1H), 7.99 (t, J = 1H), 8.15 (m, 2H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  
10.45, 14.59, 18.57, 19.04, 19.19, 33.73, 26.64, 28.94, 29.65, 31.64, 32.96, 39.21, 
42.67, 42.86, 48.81, 48.91, 49.22, 168.94, 169.86, 172.44, 173.39, 174.08.  IR cm-1; 
3290, 3084, 2925, 2854, 1694, 1626, 1545, 1444, 1234.  HRMS (ESI-TOF, positive 
mode) m/z exp [M + Na]+ calcd for C22H34N6NaO5+ 520.3469 ; found, 520.3458 [M + 
Na]+, (Δ = 1.9 ppm). 
N-hexyl-[N’-propanoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (12). Method 2. 
White solid (Yield: 78%). mp: 269-271 ˚C.  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  
0.81 (t, J = 6.3 Hz, 3H), 0.95 (t, J = 6.3 Hz, 3H), 1.15-1.21 (m, 12H), 1.35 (q, J = 7.8 
Hz, 2H), 2.06 (q, J = 7.8 Hz, 2H), 2.98 (d, J = 7.8 Hz, 2H), 3.66 (m, 4H), 4.17 (m, 2H), 
7.72 (t, J = 3.3 Hz, 1H), 7.79 (d, J = 4.0 Hz, 1H), 7.96 (t, J = 3.3 Hz, 1H), 8.10 (d, J = 
4.0 Hz, 1H), 8.16 (t, J = 3.6 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ  10.45, 
14.59, 18.57, 19.04, 22.73, 26.64, 28.95, 29.65, 31.64, 39.21, 42.67, 42.86, 48.90, 
49.22, 168.95, 169.87, 172.45, 173.41, 174.08.  IR cm-1; 3291, 3089, 2930, 2859, 1694, 
1626, 1545, 1443, 1235.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd 
for C19H35N5NaO5+  436.2530; found, 436.2554 [M + Na]+, 849.5322 [2M + Na]+, (Δ 
= 5.5 ppm). 
N-propyl-[N’-benzoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (13). Method 1. 
White powder (Yield: 85%). m.p. 233.5 ºC. Rf = 0.46 (MeOH: CH2Cl2, 10:90).  1H 
NMR (300 MHz, 30 ºC, DMSO- d6) δ  0.76 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 7.2 Hz, 
3H), 1.17 (d, J = 7.2 Hz, 3H), 1.35-1.42 (m, 2H), 2.93 (t, J = 6.6 Hz, 2H), 3.67 (m, 2H), 
3.90 (m, 3H), 4.14-4.27 (m, 2H), 7.42 (m, 2H), 7.69 (t, J = 5.1 Hz, 1H), 7.78 (m, 3H), 
8.21 (t, J = 6.6 Hz, 2H), 8.69 (t, J = 5.1 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- 
d6) δ  11.95, 18.55, 18.94, 22.91, 39.40, 42.87, 43.26, 48.91, 49.32, 127.97, 128.95, 
132.02, 134.63, 167.25, 168.95, 169.78, 172.48, 173.40.  IR cm-1; 3283, 2969, 2854,  
1696, 1622, 1542, 1446, 1234.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ 
calcd for  C20H29N5NaO5+ 442.2061 ; found, 442.2061 [M + Na]+, (Δ = 0.0 ppm). 
N-propyl-[N’-(4-nitro-benzoyl)-glycyl-L-alanyl-glycyl]-L-alanine amide (14). 
Method 2. White powder (Yield: 77%).m.p. 249-253 ºC. Rf = 0.43 (MeOH: CH2Cl2, 
10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ  0.75 (t, J = 7.2 Hz, 3H), 1.11 (d, J = 
6.9 Hz, 3H), 1.22 (d, J = 6.9 Hz, 3H), 1.32 (m, 2H), 2.93 (d, J = 6.9 Hz, 2H), 3.63 (m, 
2H), 3.88 (m, 2H), 4.13 (m, 1H), 4.22 (m, 1H), 7.69 (t, J = 5.4 Hz, 1H), 7.72 (d, J = 
7.2 Hz, 1H), 8.05 (d, J = 8.7 Hz, 2H), 8.18 (t, J = 5.4 Hz, 1H), 8.28 (t, J = 8.1 Hz, 3H), 
9.02 (t, J = 5.4 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ 11.90, 18.43, 18.87, 
22.86, 39.24, 42.84, 43.26, 48.96, 49.41, 124.20, 129.50, 140.27, 149.80, 165.77, 
169.04, 169.42, 172.60, 173.47.  IR cm-1; 3280, 2922, 2854, 1696, 16226, 1545, 1448, 
1349.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for C20H28N6NaO7+ 
487.1912 ; found, 487.1914 [M + Na]+, (Δ = 0.4 ppm). 
N-hexyl-[N’-benzoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (15). Method 1. 
White powder (Yield: 80%). m.p. 238. Rf = 0.58 (MeOH: CH2Cl2, 10:90).  1H NMR 
(300 MHz, 30 ºC, DMSO- d6) δ 0.81 (t, J = 6.9 Hz, 3H), 1.13 (d, J = 7.2 Hz, 3H), 
1.14-1.35 (m, 11H), 1.34-1.42 (m, 2H), 2.98 (d, J = 5.7 Hz, 2H), 3.66 (m, 2H), 3.89 (m, 
2H), 4.16-4.25 (m, 2H), 7.42 (m, 3H), 7.68 (s, 1H), 7.76 (d, J = 7.8 Hz, 1H), 7.83 (d, J 
= 8.4 Hz, 1H), 8.18 (t, J = 6.9 Hz, 1H), 8.69 (t, J = 6.9 Hz, 1H).  13C NMR (75 MHz, 
30 ºC, DMSO- d6) δ 14.54, 18.42, 18.84, 22.67, 26.56, 29.55, 31.58, 39.28, 42.88, 
43.26, 48.93, 49.42, 127.95, 128.96, 132.06, 134.54, 167.35, 169.01, 169.89, 172.49, 
173.48.  IR cm-1; 3283, 2929, 2857, 1696, 1622, 1542, 1448, 1235.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C23H35N5NaO5+ 484.253 ; found, 
484.2521 [M + Na]+, 945.3710 [2M + Na]+, (Δ = 1.8 ppm). 
N-hexyl-[N’-(4-nitro-benzoyl)-glycyl-L-alanyl-glycyl]-L-alanine amide (16). 
Method 1. White powder (Yield: 81%). m.p. 258.4 ºC. Rf = 0.34 (MeOH:CH2Cl2, 
10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ 0.86 (t, J = 6.6 Hz, 3H), 1.11 (d, J = 
7.2 Hz, 3H), 1.22 (m, 9H), 1.34 (t, J = 6.3 Hz, 2H), 2.97 (m, 2H), 3.68 (t, J = 6.3 Hz, 
2H), 3.94 (d, J = 6.3 Hz, 2H), 4.14-4.28 (m, 2H), 7.69 (t, J = 6.6 Hz, 1H), 7.78 (d, J = 
7.5 Hz, 1H), 8.07 (d, J = 9.0 Hz, 2H), 8.19 (t, J = 6.3 Hz, 1H), 8.27 (m, 3H), 9.03 (t, J 
= 5.1 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) δ 14.36, 18.49, 18.54, 22.66, 
26.56, 29.55, 31.57, 39.67, 43.21, 43.23, 48.82, 49.28, 124.04, 129.37, 140.26, 149.76, 
165.62, 168.90, 169.29, 172.41, 173.33. IR cm-1; 3300, 2930, 2854,  1696, 1629, 1528, 
1443, 1238.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ calcd for  
C23H34N6NaO7+ 529.2381 ; found, 529.2352 [M + Na]+, (Δ = 5.4 ppm). 
N-dodecyl-[N’-benzoyl-glycyl-L-alanyl-glycyl]-L-alanine amide (17). Method 1. 
White powder (Yield: 80%). m.p. 277.2 ºC. Rf = 0.58 (MeOH: CH2Cl2, 10:90).  1H 
NMR (300 MHz, 30 ºC, DMSO- d6) δ 080 (t, J = 6.6 Hz, 3H), 1.10 (d, J = 7.2 Hz, 3H), 
1.20-1.33 (m, 23H), 2.97 (m, 2H), 3.65 (m, 2H), 3.88 (m, 2H), 4.10-4.25 (m, 2H), 
7.44-7.51 (m, 3H), 7.68 (t, J = 5 Hz, 1H), 7.77 (d, J = 6 Hz, 1H), 7.83 (dd, J = 6.9, 1.5 
Hz, 2H), 8.19 (m, 2H), 8.70 (t, J = 5 Hz, 1H).  13C NMR (75 MHz, 30 ºC, DMSO- d6) 
δ 14.60, 18.45, 18.88, 22.74, 26.92, 3C (29.35), 5C (29.64), 29.69, 31.95, 39.19, 42.87, 
43.26, 48.91, 49.37, 127.95, 128.96, 132.05, 134.57, 167.33, 168.97, 169.84, 172.45, 
173.44.  IR cm-1; 3282, 2924, 2853, 1696, 1622, 1542, 1448, 1236.  HRMS (ESI-TOF, 
positive mode) m/z exp [M + Na]+ calcd for C29H47N5NaO5+ 568.3469 ; found, 
568.3451 [M + Na]+, (Δ= 3.1 ppm). 
N-dodecyl-[N’-(4-nitro-benzoyl)-glycyl-L-alanyl-glycyl]-L-alanine amide (18). 
Method 1. White powder (Yield: 89%). m.p. 247.1 ºC. Rf = 0.57 (MeOH: CH2Cl2, 
10:90).  1H NMR (300 MHz, 30 ºC, DMSO- d6) δ 0.83 (t, J = 6.3 Hz, 3H), 1.11-1.24 
(m, 26H), 2.98 (m, 2H), 3.66 (m, 2H), 3.93 (m, 2H), 4.11-4.23 (m, 2H), 7.71 (t, J = 5 
Hz, 1H), 7.81 (d, J = 6 Hz, 1H), 8.08 (m, 3H), 8.08 (m, 3H), 9.03 (t, J = 5.1 Hz, 1H).  
13C NMR (75 MHz, 30 ºC, DMSO- d6) δ 14.52, 16.77, 18.40, 18.85, 22.65, 26.82, 3C 
(29.26), 5C (29.55), 31.85, 39.14, 42.67, 43.11, 48.75, 49.20, 124.09, 129.39, 140.15, 
149.64, 165.50, 168.82, 169.21, 172.31, 173.24.  IR cm-1; 3299, 2921, 2851, 1696, 
1639, 1560, 1451, 1234, 1109.  HRMS (ESI-TOF, positive mode) m/z exp [M + Na]+ 
calcd for C29H46N6NaO7+ 613.3320 ; found, 613.3358 [M + Na]+, (Δ = 6.1 ppm). 
Gelation Tests. A given amount of the studied compound was weighted in a screw-
capped vial of 20 mm diameter, suspended in 1 mL of solvent and sonicated for 10 
minutes. Then, the vial was heated-up until the solid was dissolved, and afterwards left 
to spontaneously cool to room temperature. A gel (G) was considered being formed 
when no gravitational flux was observed upon vial inversion. The term weak gel (WG) 
was applied to the case where partial fluxion was observed. 
Scanning Electron Microscopy. Scanning electron micrographs were taken in a LEO 
440I microscope equipped with a digital camera. Samples of the xerogels were 
prepared by placing the gel on top of a tin plate and, after vacuum drying of the 
solvent, sputtering with Au/Pd in a Polaron SC7610 Sputter Coater from Fisons 
Instruments. 
Solid state CD. A sample of the gel was dried under vacuum and then KBr discs were 
prepared by mixing 1-2 mg of the xerogel and 200 mg of dry KBr in an agate mortar 
and pressing the mixture at 10 ton for ca. 10 minutes. Transparent discs of less than 
0.5 mm were obtained and their CD spectra were randomly taken in at least six 
different positions of the disc and averaged.[21] Spectra were recorded with a JASCO J-
810 spectropolarimeter. 
FT-IR. KBr pellets of the xerogels were prepared as stated above. Spectra were 
collected with a JASCO-FT/IR-6200 spectrometer. 
X-ray powder diffraction. Data collection was performed at room temperature on a 
Bruker D4 Endeavor X-ray powder diffractometer using Cu-Kα radiation. Samples of 
the powdered xerogels were placed on a sample holder and data were collected for 2θ 
values between 2º and 40º with a step size of 0.03º and a time step of 10 s. 
Supporting Information (see footnote on the first page of this article):  
CD, FT-IR, powder diffraction and NMR data for all the described 
compounds. 
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X-Ray Powder Diffraction 
 
Table S1. Cell dimensions (Å) derived from powder diffraction data of xerogels. 
c a
b
 
Compound[a] Solvent[b] a b c 
5 
(30) 
CH3CN 
2-Propanol 
Toluene 
Methanol 
DME 
THF 
30.4 
30.7 
29.6 
30.5 
30.6 
30.2 
8.5 
- 
8.5 
8.5 
8.5 
8.5 
4.4 
4.5 
4.4 
4.4 
4.4 
4.4 
6 
(23) 
CH3CN 
2-Propanol 
Ethanol 
Toluene 
Methanol 
THF 
23.8 
23.0 
24.5 
23.1 
23.9 
23.8 
 4.5 
4.4 
4.5 
4.5 
4.5 
4.5 
7 
(38) 
CH3CN 
2-Propanol 
CHCl3 
THF 
Toluene 
39.4 (broad) 
38.7 (broad) 
36.8 
38.3 
37.7 (broad) 
11.3 
11.3 
- 
11.3 
11.3 
4.5 
4.5 
4.5 
4.5 
4.4 
8 
(34.5) 
CH3CN 
2-Propanol 
Toluene 
Methanol 
Cyclohexanol 
30.5 
34.0 
33.9 
34.3 
33.8 
- 
11.5 
11.6 
11.6 
- 
4.4 
4.5 
4.5 
4.5 
4.5 
9 
(38) 
CH3CN 
2-Propanol 
Toluene 
Methanol 
THF 
37.2 
37.5 
37.4 
37.7 
37.9 
- 
- 
11.6 
- 
- 
4.5 
4.5 
4.5 
4.5 
4.5 
10 
(27) 
CH3CN 
2-Propanol 
Toluene 
Methanol 
Cyclohexanol 
26.9 
26.3 
26.6 
27.0 
26.9 
8.5 
8.5 
8.5 
8.5 
- 
4.5 
4.5 
4.5 
4.5 
4.5 
11 
(34.5) 
Toluene 
CHCl3 
32.7 
31.8 
11.3 
11.0 
4.5 
- 
12 
(27) 
CH3CN 
2-Propanol 
Methanol 
26.8 
26.7 
26.3 
8.4 
- 
8.4 
4.5 
4.4 
4.5 
[a]
 Calculated extended molecular length in parenthesis. [b] Xerogels were prepared by deposition of the 
gel on top of a glass slide and fast vacuum evaporation of the corresponding solvent. Although some 
extent of drying effects cannot be discarded, the slight solvent dependence of a in contrast with the 
independence of b and c for a given sample seems to indicate that those does not play a significant role on 
the observed general trends. 
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